In both TCGA and METABRIC, when gene expression was compared across different tumor types without dichotomization, BECN1 expression in the BRCA1 deletion group was significantly lower in HER2-enriched tumors (P = 0.00012 and P = 2.21E– 09, respectively) and basal-like tumors (P = 1.85E– 17 and P = 1.85E– 15, respectively) (Fig. 1I, Fig. 2I). This evidence concerns the gene BECN1 and neoplasm.